Cyfuse Biomedical K.K.

Seeking for partners on developing 3D tissues with Cell-Only ‘Micro Needle Array’ 3D Tissue Fabrication Technology

KEY ACTIVITIES 3D tissue fabrication
SECTOR: Regenerative Medicine, Drug screening
KEY WORDS: 3D Tissue, Bio 3D printer, Biofabrication system, Spheroid, Regenerative medicine, Drug screening, Disease model3D Tissue, Bio 3D printer, Biofabrication system, Spheroid, Regenerative medicine,  Drug screening
TYPE OF ACTIVITIES Research&Development, manufacturing, and sales

Product Innovations & Advantages

Cyfuse Biomedical’s Micro Needle Array Technology (MNAT) makes 100-percent-cell-only 3D biofabrication possible by tapping into cells’ natural ability to aggregate. MNAT represents a major innovation in bio 3D printing in that bio 3D printers in today’s market require some types of artificial ingredients, such as gel, for fabrication.

MNAT uses a multi-layered array of skewer-shaped fine needles as a temporary scaffold to hold spheroids (aggregated cells) in place until they naturally fuse. Skewered spheroids – measuring approximately 500μm each in diameter -- fuse together to form a cellular construct in a few days. They are kept in a medium for some additional time to achieve the desired characteristics after being removed from the needles.

Cyfuse uses its own 3D design software to shape each construct before adding spheroids to the needles. The company has two types of patented bio 3D printers: Regenova® and S-PIKE®. S-PIKE® has already certified CE marking which can be disseminated in EU market. MNAT was developed by Dr. Koichi Nakayama, currently a professor at Saga University’s Department of Regenerative Medicine and Biomedical Engineering (Japan), from his knowledge of the healing process of fractured bones while working at Kyushu University. 

 

Advantages compared to similar technology / product on the market

Regenerative therapies are currently limited to the use of cell injection or cellular sheet transplants due to a lack of advanced biofabrication technologies. Cell injection can cause some cells to drift away from the treatment site. Cellular sheets are also a less than ideal material for the treatment of damaged organs, as 3D constructs created by layering the sheets – which is a standard practice currently – cannot tightly fit into a three-dimensional space in the body. Layering the sheets require the use of artificial gel, on top of the gel that’s already in the sheets for sheet fabrication. MNAT solves all these problems by enabling the fabrication of tissue constructs in diverse shapes and sizes from the patient’s own cells with no artificial additives, boosting fusion and lowering implant rejection risks.

Cellular products fabricated with MNAT can also withstand surgical operations with superb durability compared to conventional products. In addition, these constructs can serve as powerful tools in in-vitro studies, including research on disease mechanisms and the evaluation of the efficacy of therapies.

 

Targets of cooperation

Cyfuse is currently working with several Japanese universities and research institutions in Japan with intimate knowledge of the needs of patients, clinical care providers and researchers to develop functional products. Potential applications of MNAT are quite extensive, as the technology can be used to fabricate tissues from various cell sources, including MSC and iPSC.

Cyfuse seeks opportunities to collaborate with researchers who are interested in using Micro Needle Array Technology and Cyfuse’s expertise in bio 3D fabrication to develop novel cellular constructs for their research projects. Moreover, Cyfuse envisions further partnership with industry for distributing products, manufacturing and commercialization of cellular products for practical use in EU region.

 

Company Description:  

Founded in 2010, Cyfuse Biomedical is a Tokyo-based biotechnology startup specializing in the fabrication of 3D human tissues and other advanced cellular products for regenerative medicine as well as for drug screenings. Led by CEO Shizuka Akieda, a former regenerative medicine researcher at Kyushu University and Kyushu University Hospital, the company aims to provide novel solutions for the treatment of damaged tissues and organs by bringing together its knowhow in biotechnology and high-level engineering. Cyfuse also applies the same approach to the development of laboratory tools for the evaluation of the efficacy, toxicity and metabolism of new drugs. In 2010, the New Energy and Industrial Technology Development Organization (NEDO) of Japan selected Cyfuse’s and Kyushu University’s collaborative research project on osteochondral regeneration as one of the organization’s translational research projects.

 

Type of Partnership Sought:  

  1. Commercial agreement with technical assistance

Seeking cooperation with research institute, medical institute, pharmaceutical and medical equipment company for commercialization of Cell products.

  1. Distribution services agreement

Seeking Distribution and service Partners for the product and technology.

  1. License agreement

Licencing-out to a pharmaceutical and a medical equipment company that can use Cyfuse Biomedical K.K technology for commercial uses.

  1. Research cooperation agreement

Seeking partnership with researchers and industries who can collaborate to develop 3D cellular constructs for various types of applications in Regenerative medicine and screening purpose.

 

Usability

The original software pursues usability to allow flexible designs in various shapes and pitches.

 

Operation Work Flow

Specifications

Power supply

AC100-240V, 50/60Hz

Power consumption

160VA

Layering range

plane 10×10mm, height: 8mm

Required Spheroid size

400μm (minimum)

Applicable cell type

three types (maximum)

Size

Main unit W523 × D469 × H445mm

Control box W500 × D400 × H580mm

Weight

Main unit about 39kg

Control box about 35kg

 

Product abstract

Product leaflet (PDF) 

Company website